ACL重建术当日血清MMP-3浓度较高与6年后未达到KOOS-4和IKDC可接受症状状态相关
这项描述性实验室研究基于642例初次ACL重建患者的前瞻性纵向队列,检测术当日尿CTX-II、血清PIIANP和血清MMP-3三种软骨与基质代谢生物标志物。多因素分析显示,较高的基线血清MMP-3与6年后未达到KOOS-4和IKDC的PASS阈值独立相关。术当日血液检测可能有助于识别ACL重建后6年预后不良的高风险患者。
要点
- 术前血清MMP-3较高与6年后KOOS-4和IKDC的PASS未达标相关。
- 术中关节软骨病变较重与KOOS-4和IKDC的PASS未达标均相关。
- 术前BMI较高与IKDC的PASS未达标相关,内侧半月板切除与IKDC达标相关。
核心结论
- ACL重建术当日血清MMP-3浓度较高与术后6年KOOS-4和IKDC患者可接受症状状态未达标相关。
研究设计与样本
- 描述性实验室研究,来自前瞻性纵向研究,纳入642例初次ACL重建患者,平均年龄25.02岁,60.3%为男性。
- 术前即刻采集尿液和血清样本,用免疫分析法检测u-CTX-II、s-PIIANP和s-MMP-3三种生物标志物。
- 术后6年完成IKDC主观膝关节表单和KOOS-4患者报告结局,并按PASS阈值二分类。
- 排除生物标志物离群值和缺失数据后,构建单因素和多因素logistic回归模型,以基线生物标志物浓度及手术和人口学参数为预测变量。
主要发现
- 多因素模型中,较高基线s-MMP-3(OR,0.98;P = .009)和术中关节软骨病变增加(OR,0.87;P = .040)与未达到KOOS-4 PASS相关。
- 多因素模型中,较高基线s-MMP-3(OR,0.98;P = .031)、术中关节软骨病变增加(OR,0.88;P = .045)和较高术前BMI(OR,0.91;P = .027)与未达到IKDC PASS相关。
- 与无内侧半月板撕裂相比,内侧半月板撕裂切除与达到IKDC PASS相关(OR,3.34;P = .017)。
- 单因素模型中,年龄较大和BMI较高还与未达到KOOS-4 PASS相关(均P≤ .017)。
- IKDC单因素模型中,较低基线s-PIIANP、较高u-CTX-II、年龄增加和较低术前Marx评分还与未达到PASS阈值相关(均P≤ .043)。
关键数值与推荐
- 多因素分析样本量:KOOS-4为n=366,IKDC为n=373。
- 单因素分析样本量:KOOS-4为n=411,IKDC为n=419。
- PASS阈值用于将IKDC和KOOS-4患者报告结局二分类。
临床怎么用
- 术当日血清MMP-3检测可能有助于识别ACL重建后6年预后不良的高风险患者。
- 该高风险人群可作为评估预防创伤后关节炎干预措施的目标人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of posttraumatic arthritis is elevated after anterior cruciate ligament (ACL) injury, and this can influence follow-up patient-reported outcome measures (PROMs). Biomarkers of chondral and matrix metabolism may represent a means of quantitatively evaluating the posttraumatic arthritis pathological process. PURPOSE: To assess for a longitudinal association between 3 systemic (blood and/or urine) biomarkers of chondral and matrix metabolism as measured on the day of ACL reconstruction with poor PROMs 6 years later. STUDY DESIGN: Descriptive laboratory study. METHODS: From a prospective longitudinal study, urine and serum samples were taken immediately before primary ACL reconstruction in 642 patients (mean age, 25.02 years; 60.3% men). Three biomarkers of chondral and matrix metabolism were measured using immunoassays: urinary C-terminal cross-linked telopeptide of type 2 collagen (u-CTX-II), serum N-propeptide of collagen 2A (s-PIIANP), and serum matrix metalloproteinase-3 (MMP-3). Six years postoperatively, patients completed the International Knee Documentation Committee (IKDC) Subjective Knee Form and Knee injury and Osteoarthritis Outcome Score-4 (KOOS-4) PROMs. PROMs were dichotomized based on Patient Acceptable Symptom State (PASS) thresholds. After exclusion of patients with outlier biomarker values and missing data, univariate (n = 411 for KOOS-4 and n = 419 for IKDC) and multivariate (n = 366 for KOOS-4 and n = 373 for IKDC) logistic regression models were developed with baseline biomarker concentrations and surgical and demographic parameters as predictive variables. RESULTS: In the multivariate model, higher baseline s-MMP-3 (OR, 0.98; P = .009) and increased articular cartilage pathology at surgery (OR, 0.87; P = .040) were associated with not achieving a KOOS-4 PASS. Higher baseline s-MMP-3 (OR, 0.98; P = .031), increased articular cartilage pathology at surgery (OR, 0.88; P = .045), and higher preoperative body mass index (BMI) (OR, 0.91; P = .027) were associated with not achieving a IKDC PASS. A medial meniscus tear that was resected was associated with achieving the IKDC PASS relative to no medial meniscus tear (OR, 3.34; P = .017). In the univariate modeling, older age and higher BMI were additionally associated with not achieving a KOOS-4 PASS (all P≤ .017). In the IKDC univariate modeling, lower baseline s-PIIANP, higher u-CTX-II, increasing age, and a lower preoperative Marx score were additionally associated with failing to achieve the PASS threshold (all P≤ .043). CONCLUSION: Increased s-MMP-3 concentration on the day of surgery was associated with failing to achieve the PASS threshold for both the KOOS-4 and IKDC PROMs at the 6-year time point after ACL reconstruction. CLINICAL RELEVANCE: This day of surgery blood test may be helpful in identifying patients at risk of a poor outcome 6 years after ACL reconstruction. In turn, this could help define a target group for evaluating interventions aimed at preventing posttraumatic arthritis.
引用
- Batty LM, Huynh M, Webster KE, et al. Higher Day of Surgery Serum Matrix Metalloproteinase-3 Concentration Is Associated With Failing to Achieve the KOOS-4 and IKDC Patient Acceptable Symptom State at 6 Years After ACL Reconstruction. Am J Sports Med. 2026. PMID: 41711030. doi:10.1177/03635465261416921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。